Interferons in HIV and related diseases

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Interferon-alpha (IFN-α) has broad-spectrum activity and has been explored in HIV-infected populations.
• Efficacy in Kaposi's sarcoma (KS) varies with CD4 cell counts, with higher response rates in patients with elevated counts.
• Investigated for opportunistic infections and in combination with antiretroviral therapy like zidovudine.

Purpose of the Study:

• To evaluate the efficacy of interferon-alpha in HIV-infected patients with Kaposi's sarcoma, opportunistic infections, and viral hepatitis.
• To assess the impact of interferon-alpha on CD4 cell counts and opportunistic infection rates in HIV patients.
• To determine the effectiveness of interferon-alpha in treating co-infections such as hepatitis B and C in individuals with HIV.

Main Methods:

• Clinical trials involving HIV-infected patients with Kaposi's sarcoma, opportunistic infections, and viral hepatitis.
• Comparison of interferon-alpha treatment versus placebo in asymptomatic HIV patients.
• Combination therapy trials using interferon-alpha with zidovudine in HIV patients.

Main Results:

• Response rates for Kaposi's sarcoma exceeded 45% in HIV patients with higher CD4 cell counts.
• In asymptomatic HIV patients, interferon-alpha was associated with higher CD4 cell percentages and fewer opportunistic infections.
• Hepatitis B DNA clearance occurred in 37% of HIV patients treated with interferon-alpha, compared to 17% spontaneous clearance.
• 50-75% of hepatitis C patients showed reduced transaminases with interferon-alpha treatment.

Conclusions:

• Interferon-alpha demonstrates significant benefit for certain HIV-infected patients.
• Efficacy is noted in managing Kaposi's sarcoma, hepatitis B, and hepatitis C co-infections.
• While effective, careful consideration of dosage and potential side effects is warranted, especially in combination therapies.